EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanotechnology‐Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives

Min Yi, Yiming Li iD, Hui Jie, Senyi Deng iD

Thoracic Cancer · 2025-07 · 16 (14)

DOI: 10.1111/1759-7714.70134 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 18.07.2025. Verfasst von Min Yi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Delivery Systems, Nanotechnology, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains one of the leading causes of cancer‐related deaths worldwide, underscoring the urgent need for transformative therapeutic strategies. Conventional treatments face critical limitations, including poor targeting efficiency, systemic toxicity, and resistance to targeted therapies. Nanotechnology offers promising solutions by enabling enhanced drug stability, bioavailability, and targeting precision. This review integrates recent advancements in nanotechnology‐driven drug delivery systems with a particular focus on computational tools that optimize nanocarrier design. Molecular simulations, quantum mechanics, and AI‐driven models have emerged as powerful approaches to streamline development, accelerate innovation, and enable personalized therapies. Clinically, several nanocarrier‐based formulations have been associated with favorable therapeutic outcomes in lung cancer patients, including extended progression‐free survival and reduced treatment‐related toxicity. Despite these advancements, challenges remain in scaling production, ensuring regulatory compliance, and achieving broad clinical adoption. By addressing these barriers through interdisciplinary collaboration, nanotechnology holds the potential to revolutionize lung cancer therapy and set new standards for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrug Delivery SystemsNanotechnologyAntineoplastic AgentsHumans

Stichwörter der Autor:innen

computational designdrug deliverylung cancermolecular simulationsnanotechnology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Yiming Li, Senyi Deng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yi, M., Li, Y., Jie, H., & Deng, S. (2025). Nanotechnology‐Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives. Thoracic Cancer, 16(14). https://doi.org/10.1111/1759-7714.70134

Vancouver

Yi M, Li Y, Jie H, Deng S. Nanotechnology‐Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives. Thoracic Cancer. 2025;16(14). doi:10.1111/1759-7714.70134

BibTeX
@article{Yi2025,
  author = {Yi, Min and Li, Yiming and Jie, Hui and Deng, Senyi},
  title = {Nanotechnology‐Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives},
  journal = {Thoracic Cancer},
  year = {2025},
  volume = {16},
  number = {14},
  doi = {10.1111/1759-7714.70134}
}
Kostenlos starten →